Compare Alcon AG (ALC) vs SOLAI Limited (SLAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs SOLAI Limited — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while SOLAI Limited trades at $3.04 (market cap $14.40M). The key difference: Alcon AG is far larger — about 2270.1× SOLAI Limited's market cap, and Alcon AG pays a 0.54% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| ALC | SLAI | |
|---|---|---|
Market Cap | $32.69B | $14.40M |
Sector | Health | Technology |
52-Week High | $92.22 | $43.75 |
52-Week Low | $62.02 | $2.74 |
Enterprise Value | $36.28B | $14.04M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SLAI trades at $3.27, up 5.48% today, but faces significant financial challenges with negative profitability metrics including a -134.63% net income margin and -$33.88M net loss for 2025. The company recently completed a 7:1 reverse stock split and acquired a 51% stake in NEURALAND while receiving NYSE listing standard notices. Technical indicators show a bearish trend with support at $3 and resistance at $4.
Despite recent acquisitions and product launches, SLAI's persistent losses and negative cash flow present substantial investment risks. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment amid ongoing financial restructuring and competitive pressures in the AI infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
